First Case of Foot Drop Associated with Capecitabine in a Patient with Thymidylate Synthase Polymorphism

Capecitabine, an oral prodrug of 5-FU, has been approved by the FDA for use in patients with breast and colon cancers. In addition, capecitabine is commonly used in patients with other malignancies such as pancreatic, gastroesophageal, and hepatobiliary tract cancers. Though cerebellar toxicity is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilks, Andrew B, Saif, Muhammad W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2017
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325748/
https://www.ncbi.nlm.nih.gov/pubmed/28280649
http://dx.doi.org/10.7759/cureus.995

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325748/
https://www.ncbi.nlm.nih.gov/pubmed/28280649
http://dx.doi.org/10.7759/cureus.995

Ejemplares similares